In the FHCRC phase-I experiment, third-generation anti-CD20 CAR-T cells containing CD28 and 4-1BB domains were used to treat MCLs and intolerant B-cell lymphomas. The gene discussed is CD28; the disease is B-cell non-Hodgkin lymphoma.